Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma
C. S. Koivisto, M. Parrish, S. B. Bonala, S. Ngoi, A. Torres, J. Gallagher, R. Sanchez-Hodge, V. Zeinner, G. J. Nahhas, B. Liu, D. E. Cohn, F. J. Backes, P. J. Goodfellow, H. M. Chamberlin, G. Leone
This study evaluates enzalutamide's efficacy and resistance development in a mouse model of type-I endometrial carcinoma, finding it reduces tumor burden initially but promotes resistance with prolonged use.
bioRxiv · Dec 6, 2019Cancer Biology